水羊股份(300740.SZ):暫未採用AI技術參與研發
格隆匯4月7日丨水羊股份(300740.SZ)在投資者互動平台表示,公司堅持“研發賦能品牌”戰略,持續加大研發投入,內外自研項目與產學研同步開展,目前已成功實現多款原料自主掌控。水羊自主研發的國內第一款粧食同源的新原料“吡咯並喹啉醌二鈉鹽”(簡稱PQQ二鈉鹽),已得到國家食藥監局批准;中國獨有新原料“黑參提取物”完成備案;公司暫未採用AI技術參與研發,但將持續加大研發投入,推動前沿科技研究、創新原料開發、產品開發服務,後續具體研發成果,敬請持續關注公司公開披露的信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.